Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.34 and traded as high as $1.42. Cortexyme shares last traded at $1.33, with a volume of 77,816 shares changing hands.
Cortexyme Trading Down 5.0 %
The stock has a market cap of $40.10 million, a price-to-earnings ratio of -0.45 and a beta of 1.40. The stock has a fifty day simple moving average of $1.65 and a 200-day simple moving average of $1.34.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- What Are Trending Stocks? Trending Stocks Explained
- Axon: Long-Term Outlook Is Strong Despite Federal Budget Worries
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks Powering the Future of Autonomous Driving
- Energy and Oil Stocks Explained
- These 3 Stocks Are Generating Massive Returns on Capital
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
